Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This latest development is expected to contribute to Medtronic's (MDT) pain therapy business in the coming months.

Medtronic (MDT) Gets FDA Nod for Revised Neuromodulation Labeling

We think that Medtronic currently is a better pick compared to Intuitive Surgical. MDT stock trades at about 5.7x trailing revenues, compared to around 18.5x for ISRG.

Here's Why Medtronic Is A Better Pick Over Intuitive Surgical Stock

DUBLIN, March 17, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) has approved revised commercial labeling for the Intellis™ Platform with Differential Target Multiplexed (DTM™) programming for the treatment of chronic, intractable back and leg pain. The new labeling will include study outcomes from a multicenter randomized control trial reflecting superior back pain relief with DTM SCS when compared to conventional SCS.

Medtronic Receives Approval for U.S. Labeling of the Intellis™ Platform Showing Superior Back Pain Relief When Using DTM™ Spinal Cord Stimulation

Medtronic plc (MDT) Presents at Oppenheimer 31st Annual Healthcare Conference (Transcript)

Amphenol

Chubb

Danaher

Intercontinental Exchange

International Flavors & Fragrances

Walmart

In this article series, we provide a summary of upcoming ex-dividend dates.

Upcoming Ex-Dividend Dates: March 16-29, 2021

NEX: CHIP CALGARY, AB, March 12, 2021 /PRNewswire/ - Health Logic Interactive Inc. ("Health Logic" or the "Company") (NEX: CHIP), is pleased to announce the hiring of Mr. David Barthel, as the Chief Executive Officer for Health Logic.

Health Logic Interactive is Pleased to Announce the Appointment of Experienced MedTech Executive as CEO

DUBLIN, March 8, 2021 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Friday, March 5, 2021, approved the fiscal year 2021 fourth quarter cash dividend of $0.58 per ordinary share, representing a 7.4 percent increase over the prior year. This quarterly declaration...

Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2021

Golar LNG

The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share increase at a compound annual growth rate of nearly 2% over the past five years. The share price of the benchmark index for the U.S. stock market traded at $3,841.94 at close on Friday, up by more than 90% over the past five years through March 5.

A Trio of Fast-Growing Revenue Stock Picks

Abbott Labs

Johnson & Johnson

Masimo

These four MedTech stocks -- ABT, JNJ, MDT and MASI -- are expected to gain enormously from FDA's SaMD Action Plan 2021.

4 Stocks to Watch as FDA Action Plan Stresses MedTech Digitization

Becton, Dickinson and Co.

DexCom

Axonics ModulationTechnologies Inc

When the market is expensive and overbought like the current one is, it is very important to stay with companies that not only have solid earnings potential but also have upcoming catalysts that can help move the shares higher.

4 Medical Technology Leaders Have Upcoming Catalysts That Could Be Huge

Medtronic's (MDT) REVERSE analysis highlights the role played by CRT to slow the progression of HF, thus reinforcing the strong clinical evidence supporting CRT.

Medtronic's (MDT) REVERSE Trial Indicates CRT's Benefits for HF

The latest back-to-back incidents will, undoubtedly, create a major drag in Medtronic's (MDT) VAD performance.

Medtronic's (MDT) HVAD Pump Kit Recall Classified as Class I

Medtronic PLC (MDT) Presents at Cowen Healthcare Broker Conference Call - (Transcript)

The FDA has classified another recall of Medtronic Plc's (NYSE: MDT) HeartWare HVAD ventricular assist device as a Class I event in light of the potential for serious harm. Medtronic is recalling 157 HVAD pump implant kits from the U.S. after receiving complaints that some devices have failed to start or restart promptly.

Medtronic To Recall HeartWare Implant Kits After Patient Deaths

DUBLIN, March 2, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for patients with mild heart failure (HF). This new analysis...

New Analysis of REVERSE Trial Reveals Benefits of CRT for More Patients with Heart Failure

In Coronary, the ongoing issue related to the China drug-eluting stent national tender, Medtronic (MDT) is currently winning share globally.

Medtronic's (MDT) Market Share Grows Amid COVID-19 Woes

Medtronic plc (MDT) CEO Geoffrey Martha on Q3 2021 Results - Earnings Call Transcript

Medtronic (MDT) procedure volumes hurt by resurgence of COVID-19 cases despite increased demand for related diagnostics and therapies.

Medtronic's (MDT) Q3 Earnings Beat Estimates, Margins Fall

Medtronic stock inched higher Tuesday after the medical technology giant beat Wall Street's quarterly profit estimates, but sales were just in line on the continued pandemic impact. The post This Medical Stock Just Retook Its Buy Point On Unexpected Earnings Beat appeared first on Investor's Business Daily.

This Medical Stock Just Retook Its Buy Point On Unexpected Earnings Beat

The medical device giant's CEO tells Barron's that the impact of rising cases on hospital capacity this January led to a pullback for the company.

Medtronic's Latest Earnings Could Be a Warning for Other Medical Device Companies

Medtronic (MDT) delivered earnings and revenue surprises of 12.17% and -0.03%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Beats Q3 Earnings Estimates

Medtronic PLC reported Tuesday fiscal third-quarter profit that fell less than expected, while sales rose more than forecast. The medical technology and services company's stock slipped 2.0% in premarket trading, after rising 2.1% on Monday.

Medtronic profit falls less than forecast, while revenue rises above expectations

Shares of Medtronic (NYSE:MDT) fell 0.2% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 10.42% over the past year to $1.29, which beat the estimate of $1.15.

Medtronic: Q3 Earnings Insights

- Q3 Revenue of $7.8 Billion Increased 0.8% as Reported and Decreased 1.0% Organically - Q3 GAAP Diluted EPS of $0.94; Q3 Non-GAAP Diluted EPS of $1.29 DUBLIN, Feb. 23, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year...

Medtronic Reports Third Quarter Fiscal 2021 Financial Results

Medtronic stock is scheduled to report its fiscal third-quarter results on Tuesday, February 23. We expect Medtronic to likely post revenues in-line, and earnings above the consensus estimates.

News for Medtronic Stock (MDT)